Biocon Biologics Ltd (BBL), a global biosimilars company and subsidiary of Biocon Ltd (BSE: 532523, NSE: BIOCON), has announced the launch of Nepexto®, a biosimilar of Enbrel® (Etanercept), in Australia. The product will be marketed through its local partner, Generic Health, a prominent player in generic and prescription medicines, to broaden patient access across the region.

Etanercept is a TNF (tumor necrosis factor) inhibitor used to treat several autoimmune conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis.

Nepexto® received EU marketing authorization in 2020 and has since seen wide adoption across European markets. With the global integration of Biocon’s biosimilars business in 2022, BBL is now leveraging its strengthened portfolio and commercial reach to introduce Nepexto® in new geographies, enhancing its position in the immunology space.